Nexalin Technology Announces Clinical Study Data In Major Depressive Disorder And Publication Of Clinical Trial Results In Leading Scientific Journal 'Brain Stimulation'
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology announced positive clinical study results for its DIFS® technology combined with escitalopram in treating major depressive disorder. The study showed significant improvement in two-thirds of patients receiving the combination therapy compared to one-third receiving medication alone.
June 26, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's clinical study results show significant improvement in treating major depressive disorder using its DIFS® technology combined with escitalopram. This positive outcome could boost investor confidence and potentially drive the stock price up.
The positive clinical study results demonstrate the efficacy of Nexalin's DIFS® technology in combination with escitalopram, showing significant improvement in patients with major depressive disorder. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100